About Acepodia
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients.
Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens.
Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
|
|
|
11-50 employees
View all Acepodia employees
|
|
Biotechnology
|
|
1600 Harbor Bay Pkwy, Suite 140, Alameda, California 94502, US
|
|
2016
|
|
Biotechnology, Oncology, Cell Therapy, Car, Nk Cells, Allogeneic, Off-The-Shelf, Cancer Cell Immunotherapy, Interdisciplinary Technology
|
Acepodia Alternatives
Frequently Asked Questions about Acepodia
Sonny Hsiao is the CEO of Acepodia. To contact Sonny Hsiao email at [email protected].
Acepodia Staff Directory
Search Acepodia Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
